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Abstract
Background The efﬁcacy and safety of the association of
celecoxib [a selective cyclooxygenase-2 (COX-2) inhibi-
tor] and pregabalin (commonly used to control neuropathic
pain), compared with monotherapy of each, were evaluated
for the treatment of chronic low-back pain, a condition
known to be due to neuropathic as well as nociceptive pain
mechanisms.
Materials and methods In this prospective randomized
trial, 36 patients received three consecutive 4-week treat-
ment regimes, randomly assigned: celecoxib plus placebo,
pregabalin plus placebo, and celecoxib plus pregabalin. All
patients were assessed by using a visual analogue scale
(VAS, 0–100 mm) and the Leeds Assessment of Neuro-
pathic Symptoms and Signs (LANSS) pain scale by an
investigator blinded to the administered pharmacological
treatment.
Results Celecoxib and pregabalin were effective in
reducing low-back pain when patients were pooled
according to LANSS score. The association of celecoxib
and pregabalin was more effective than either monotherapy
in a mixed population of patients with chronic low-back
pain and when data were pooled according to LANSS
score. Adverse effects of drug association and monother-
apies were similar, with reduced drug consumption in the
combined therapy.
Conclusions Combination of celecoxib and pregabalin is
more effective than monotherapy for chronic low-back
pain, with similar adverse effects.
Keywords Pregabalin  Celecoxib  Low-back pain 
Polypharmacotherapy
Introduction
Low-back pain is the ﬁfth most common reason for all
physician visits in the USA [1, 2]. Many patients have self-
limited episodes of acute low-back pain and do not seek
medical care [3]. Among those who do seek medical care,
pain, disability, and return to work typically improve rap-
idly in the ﬁrst month [4]. However, up to one-third of
patients report persistent back pain of at least moderate
intensity 1 year after an acute episode [5, 6].
Successful treatment of pain depends on identiﬁcation of
the involved mechanism and use of appropriate therapeutic
approaches.
Woolf et al. [7] proposed that pain symptoms and syn-
dromes should be classiﬁed into two broad mechanism-
based pain categories: tissue-injury pain (nociceptive) or
nervous-system-injury pain (neuropathic). Chronic low-
back pain (LBP) has been shown to be the result of neu-
ropathic as well as nociceptive pain mechanisms [8–11].
Based on this evidence, it has been suggested that antide-
pressants and/or anticonvulsants in combination with either
opioids, traditional nonsteroidal anti-inﬂammatory drugs or
muscle relaxants could be useful in the treatment of this
condition [11–13].
Even if there is increasing knowledge that different
mechanismsofpainrequireappropriatetreatmentsandoften
polypharmacotherapy, and although drug combination is
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spectivestudiesconcerningtherelativeefﬁcacyandsafetyof
polypharmacotherapy compared with monotherapy are still
relatively few [14–20].
Among the most commonly used agents to control
neuropathic pain is pregabalin, which has been validated in
different clinical settings [14, 21–23], while celecoxib is a
selective COX-2 inhibitor that has been proved to be
effective in the treatment of different pain models that are
considered predominantly of nociceptive origin [24–26].
Aim of this prospective, single-blind, randomized study
was to compare the safety and efﬁcacy of the association of
celecoxib and pregabalin with monotherapy of each for
treatment of chronic low-back pain in a mixed population
of patients affected by chronic low-back pain and then to
interpret the results by pooling the same patients according
to Leeds Assessment of Neuropathic Symptoms and Signs
(LANSS) pain scale [27, 28].
Methods
In this 12-week, double-blind, prospective study, per-
formed at our institution from 2006 to 2008, we compared
the efﬁcacy and tolerability of the combination of a
selective COX-2 inhibitor, anti-inﬂammatory drug, cele-
coxib and an antineuropathic drug, pregabalin, versus
either celecoxib or pregabalin plus placebo, in the treat-
ment of chronic LBP due to disc prolapse, lumbar spon-
dylosis, and/or spinal stenosis.
The study was performed in accordance with the ethical
standards of the 1964 Declaration of Helsinki as revised in
2000 and approved by the Institutional Review Board.
Informed consent was obtained from each subject at
recruitment.
Patient population
Of the originally enrolled 42 patients, 36 completed the
study, 16 men and 20 women (Table 1).
Inclusion criteria were the following:
• Chronic low-back pain (symptoms duration:
[6 months, mean: 13 ± 6 months) due to disc pro-
lapse, lumbar spondylosis, and/or spinal stenosis;
• Minimum VAS at recruitment:[40 mm
• Age:[18 years,\75 years;
• Informed consent.
Exclusion criteria:
• Previous back surgery;
• Diabetes;
• Neurological disease;
• Cardio-renal disease;
• History of gastric ulcers or intestinal bleeding;
• Known allergy to the drugs under study;
• Alcohol or drug abuse.
Once the patient was found eligible to participate in the
study, informed consent was obtained.
Assessment
Primary outcomes was mean pain reduction following
different treatments regimes. Secondary outcomes were
adverse effects due to the treatments under study.
Before starting treatment, demographic and anthropo-
metric data, as well as a medical history, were collected.
All patients were assessed by visual analogue scale
(100 mm), LANSS, and radiographically.
Visual analogue scale was evaluated at patient recruit-
ment and before and after any 4-week treatment period by
an investigator blinded to the administered pharmacologi-
cal treatment.
The LANSS pain scale consisted of a two-sided A4
sheet and was designed to be used in interview format
during a single session. The interview, performed at
recruitment, consisted of the clinician reading the ques-
tionnaire and asking the patient whether the description
matched their pain characteristics in the preceding week.
This session was followed by a bedside examination for
any sensory dysfunction and speciﬁcally for allodynia and
for altered pinprick threshold (PPT). Allodynia was judged
Table 1 Demographic and anamnestic patient data (n = 36)
Patient characteristics Total number
Sex
Male 16
Female 20
Race
White 33
Black 1
Asian 2
Mean age (years) 53 ± 16
Mean weight (kg) 71 ± 14
Smoking habits
Smoker 13
Ex-smoker 5
Nonsmoker 18
Previous use of medications 30
Causes of LBP (may be associated)
Disc prolapse 17
Lumbar spondylosis 14
Spinal canal stenosis 7
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123to be present when pain was elicited by the gentle stroke of
a piece of cotton over the painful area in comparison with a
nonpainful area. PPT was determined by comparing the
response to a 23-gauge needle mounted inside a 2-mL
syringe barrel placed onto the skin in nonpainful and then
painful areas several times. PPT was deﬁned as a sharp
sensation in relation to gentle needle placement in a painful
area. According to the LANSS pain scale, the frequency of
each item of the ﬁve pain symptoms, as well as the two
sensory examination items, was calculated for every
patient. Dysesthesia and autonomic dysfunction were given
a score of 5 each, if present. Evoked pain was given a score
of 3. Paroxysmal pain was given a score of 2. Thermal pain
was given a score of 1. For testing sensory dysfunction,
allodynia, if found, was given a score of 5, and altered PPT
was given a score of 3. Accordingly, the total summed
scores had a maximum of 24 points. Patients with a score
less than 12 were considered unlikely to have neuropathic
low-back pain, whereas patients with a score of 12 or more
were considered to have a neuropathic element that con-
tributed to their low-back pain. Neither psychological sta-
tus nor social class of patients was included in the study.
Treatment regime
After a discontinuation period of at least 7 days from any
previous analgesic treatment and between treatments, each
patient received the following three consecutive treatments
regimes:
• Celecoxib (approximately 3–6 mg/kg/die) ? placebo;
• Pregabalin (approximately 1 mg/kg/die the ﬁrst week
and then 2–4 mg/kg/die) ? placebo;
• Celecoxib (approximately 3–6 mg/kg/die) plus pregab-
alin (approximately 1 mg/kg/die the ﬁrst week and then
2–4 mg/kg/die).
Each treatment lasted 4 weeks, with 1-week discontin-
uation between treatments (Table 2). The sequence of
treatments in each patient was randomly assigned as fol-
lows, based on consecutive recruitment order: ﬁrst patient
received celecoxib ? placebo, pregabalin ? placebo,
celecoxib ? pregabalin; second patient received pregaba-
lin ? placebo, celecoxib ? pregabalin, celecoxib ? pla-
cebo; third patient received celecoxib ? pregabalin,
celecoxib ? placebo, pregabalin ? placebo; and so on.
Concomitant use of antidepressants and/or anticonvul-
sants, opioids, nonsteroidal anti-inﬂammatory drugs or
muscle relaxants was not permitted during the 12-week
study.
Statistical analysis
Descriptive statistics were determined by calculation of the
mean and standard deviation (±SD). Statistical analysis
was performed with Student’s t test.
Stratiﬁcation on the basis of LANSS pain scale score
(with a score of 12 or more as the cutoff point) was done
for intergroup comparison.
Results throughout the text, tables, and ﬁgures are pre-
sented as mean ± SD unless otherwise speciﬁed, and sta-
tistical signiﬁcance was deﬁned as P\0.05. Sample size
was chosen according to a minimum expected difference in
pain control of different treatment regimes of 10%.
Results
Of the 42 patients initially recruited for the study, 6 deci-
ded to discontinue the treatment or did not present them-
selves at the programmed controls and were then excluded
from data analysis. Among these six patients, four (one
taking celecoxib alone, one taking pregabalin alone, two
taking pregabalin ? celecoxib) refused to continue the
treatment within the ﬁrst 2 weeks due to reported epigas-
tralgia and/or nausea, one patient was lost to follow-up
after 22 days due to logistical problems (work travelling
outside Italy), and one due to intercurrent trauma (car
accident). All presented data will be referred to the
remaining 36 patients who completed the study and were
available at follow-up.
Table 2 Experimental setup
Week Action Cohort 1 (N = 12) Cohort 2 (N = 12) Cohort 3 (N = 12)
0 Patient’s recruitment/assessment/randomization. Any treatment discontinuation
1 VAS assessment Starts treatment C Starts treatment C ? P Starts treatment P
5 Treatment discontinuation and VAS assessment
6 VAS assessment Starts treatment P Starts treatment C Starts treatment C ? P
10 Treatment discontinuation and VAS assessment
11 VAS assessment Starts treatment P ? C Starts treatment P Starts treatment C
15 Treatment discontinuation and VAS assessment
C celecoxib ? placebo, P pregabalin ? placebo, C ? P celecoxib ? pregabalin
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123Of 36 patients, 20 had LANSS pain scale score \12,
while the remaining 16/36 were rated[12.
Table 3 summarizes mean ± standard deviation of
recorded VAS immediately prior to the beginning of each
treatment regime and after the 4-week treatment period.
According to the statistical analysis of data, also provided in
the same table, celecoxib ? placebo and pregaba-
lin ? placebo did produce a statistically signiﬁcant reduc-
tion of reported pain, in patients with LANSS score\12
(P = 0.01) and in patients with LANSS score [12
(P = 0.03), but not in the general population of patients
studied. On the contrary, the association pregaba-
lin ? celecoxib resulted in a statistically signiﬁcant reduc-
tion of self-reported pain when considering either all the
recruitedpatientsorthesubpopulationsdividedaccordingto
LANSS score. The drug combination also proved more
effective that pregabalin alone and more effective than
celecoxibalone,exceptforpatientswithLANSSscore\12.
Table 3 Self-reported VAS before and after each 4-week treatment regime
Pretreatment End of
4-week
treatment
P value
(end of treatment
versus
pretreatment)
P value
(drug combination
versus
celecoxib ? placebo)
P value
(drug combination
versus
pregabalin ? placebo)
Mean SD Mean SD
Celecoxib ? placebo (all patients,
N = 36)
45.1 13.1 39.5 12.2 0.06
Celecoxib ? placebo (LANSS\12,
N = 20)
43.8 12.9 32.5 15.5 0.01
Celecoxib ? placebo (LANSS[12,
N = 16)
46.8 13.6 45.7 14.3 0.8
Pregabalin ? placebo (N = 36) 48.1 14.2 43.1 13.5 0.12
Pregabalin ? placebo (LANSS\12,
N = 20)
49.4 13.2 50.7 13.8 0.76
Pregabalin ? placebo (LANSS[12,
N = 16)
47.2 15.0 36.3 12.7 0.03
Celecoxib ? pregabalin (all patients,
N = 36)
46.3 13.8 28.6 15.1 0.0001 0.001 0.0001
Celecoxib ? pregabalin (LANSS\12,
N = 20)
45.1 14.2 32.9 13.9 0.009 0.9 0.0002
Celecoxib ? pregabalin (LANSS[12,
N = 16)
47.9 15.2 23.1 14.6 0.0001 0.0001 0.01
Bold values indicate P\0.05
Mean V.A.S. reduction after treatment
-5 0 5 10 15 20 25 30 35 40 45 50 55
Celecoxib + placebo (All the patients, N = 36)
Celecoxib + placebo (LANSS < 12, N = 20)
Celecoxib + placebo (LANSS > 12, N = 16)
Pregabalin + placebo (All the patients, N = 36)
Pregabalin + placebo (LANSS < 12, N = 20)
Pregabalin + placebo (LANSS > 12, N = 16)
Celecoxib + Pregabalin (All the patients, N = 36)
Celecoxib + Pregabalin (LANSS < 12, N = 20)
Celecoxib + Pregabalin (LANSS > 12, N = 16)
% V.A.S. reduction
Fig. 1 Percentage pain reduction at the end of each 4-week treatment regime: mean VAS at the end of treatment/mean pretreatment VAS
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123Figure 1 summarizes the percentage pain reduction
following the different treatment regimes. When all
patients were considered, celecoxib alone provided 12.4%
pain reduction, pregabalin alone 10.4%, and their combi-
nation 38.2%. The largest pain reduction (51.8%) was
observed with the association pregabalin ? celecoxib in
patients with LANSS score[12.
Drugs consumption
The dosage of each drug was established at the beginning
of each treatment period on the basis of each patient
weight, but it could be modiﬁed during the treatment
course by the physician, according to the pain and side-
effects reported by the patients. Overall drug consumption
by any single patient was tracked. During cele-
coxib ? placebo treatment, mean celecoxib consumption
was 4.12 ± 0.93 mg/kg/die; during pregabalin ? placebo
treatment it was 2.12 ± 0.69 mg/kg/die; and during cele-
coxib ? pregabalin treatment it was 3.75 ± 0.86 and
1.78 ± 0.64 mg/kg/die, respectively. The difference of
pregabalin and celecoxib consumption, when used in
association, compared with monotherapies, was statisti-
cally signiﬁcant for pregabalin (P\0.05) but not for
celecoxib (P = 0.09).
Adverse effects
Of the initially recruited 42, 4 (9%) discontinued treatment
early due to side-effects and were not considered for fur-
ther analysis of results. Of the remaining 36 patients, side-
effects were recorded in 16 (44.4%) patients but did not
require treatment discontinuation. Four had epigastralgia
and nausea during celecoxib ? placebo treatment, ﬁve
reported nausea or dizziness after pregabalin ? placebo,
and seven experienced similar symptoms during treatment
with celecoxib plus pregabalin.
Discussion
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are the
most frequently prescribed medications worldwide and
are widely used for patients with low-back pain. Selec-
tive COX-2 inhibitors are currently available and used
for patients with low-back pain. A recently published
systematic Cochrane review of randomized controlled
trials has shown the efﬁcacy of NSAIDs and COX-2
inhibitors in the treatment of nonspeciﬁc low-back pain.
In 65 trials (total number of patients = 11,237) statisti-
cally signiﬁcant effects were found in favor of NSAIDs
compared with placebo, but at the cost of statistically
signiﬁcant more side-effects. COX-2 NSAIDs had
statistically signiﬁcantly fewer side-effects than tradi-
tional NSAIDs [29].
Pregabalin is a ligand for the alpha-2-delta subunit of
voltage-gated calcium channels with anticonvulsant, anal-
gesic, and anxiolytic properties. It has predictable absorp-
tion across the gastrointestinal tract, is neither metabolized
nor protein bound, and has minimal drug–drug interactions.
Pregabalin has been widely studied for the treatment of
neuropathic pain and was shown in prospective randomized
clinical trials to be effective for postherpetic neuralgia and
painful diabetic peripheral neuropathy, with approximately
50% responder rates. Pregabalin is also usually well tol-
erated in most patients, with infrequent severe adverse
effects [30]. It has also been proved to be effective in other
painful conditions, such as ﬁbromyalgia [31, 32].
Pregabalin and its older companion, gabapentin, have
already been successfully used in combination with other
analgesic drugs to improve pain control. Gilron et al. [16]
ﬁrst reported on the efﬁcacy and safety of a combination of
gabapentin and morphine compared with that of each as a
single agent in patients with painful diabetic neuropathy or
postherpetic neuralgia. In 41 patients who completed the
trial, gabapentin-morphine combination showed signiﬁ-
cantly better pain control (P\0.05) versus placebo,
gabapentin, and morphine. The group from the Ospedale
Tor Vergata in Rome more recently published the Multi-
center Italian Study, which compared the efﬁcacy, safety,
and quality of life of combination therapy with controlled-
release (CR) oxycodone plus pregabalin versus mono-
therapy in patients with neuropathic pain [33]. This study
showed in 409 patients that the combination of CR oxy-
codone plus pregabalin and CR oxycodone monotherapy
were both more effective for alleviating neuropathic pain
than was pregabalin monotherapy (reduction in an 11-point
numerical rating scale of 80%, 76%, and 46%, respec-
tively; P = 0.003). Extremely signiﬁcantly greater
improvements from baseline in quality of life were repor-
ted with combination therapy than with monotherapy
(P = 0.0009), and combination therapy also allowed dose
reduction of both agents (22% for CR oxycodone and 51%
for pregabalin) compared with dosages of the respective
monotherapies.
Other studies compared the efﬁcacy of pregabalin or
gabapentin in combination with different analgesic agents
for postoperative pain. Gilron et al. [15] demonstrated, in
a placebo-controlled randomized clinical trial on pain
after abdominal hysterectomy, that perioperative admin-
istration of a combination of gabapentin and rofecoxib
was signiﬁcantly superior (P\0.05) over monotherapy,
with similar adverse effects, except sedation which was
more frequent with gabapentin alone. The association of
gabapentin with celecoxib was found by Parsa and
co-workers [18] to be signiﬁcantly superior (P\0.001) in
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123reducing postoperative pain and opioid requirements than
celecoxib alone in patients undergoing bilateral subpectoral
breast augmentation.
Recently the association of pregabalin and of bupr-
enorphine TDS and pregabalin in the treatment of low-back
pain has been described [19]. In 22 patients buprenorphine
provided a meaningful pain reduction (VAS 82.75 ± 15
versus 138.25 ± 5, P\0.01), but the association of low
doses of pregabalin allowed a further reduction of the VAS
(P\0.01).
Michael Bennett in 2001 [27] introduced the Leeds
Assessment of Neuropathic Symptoms and Signs (LANSS)
pain scale. The LANSS has subsequently been tested and
validated in several settings, with sensitivity and speciﬁcity
ranging from 82% to 91% and 80% to 94%, respectively,
compared with clinical diagnosis [34]. After Baron and
Binder [8] ﬁrst introduced in 2004 the concept of mixed
pain for sciatica, studies were published that conﬁrmed the
participation of nociceptive as well as neuropathic mech-
anisms of low-back pain. Kaki et al. [11] applied the
LANSS pain scale in a total of 1,169 patients from 117
centers; 639 patients (54.7%) had scores of 12 points or
more, which suggested a neuropathic type of pain, and 530
patients (45.3%) had scores of less than 12, which sug-
gested a nociceptive type of pain. These authors concluded
that neuropathic pain is a major contributor to chronic low-
back pain and that the LANSS pain scale is a useful tool to
distinguish patients with neuropathic pain from those with
nociceptive pain.
To our knowledge, this is the ﬁrst report of the efﬁcacy
of both celecoxib and pregabalin for the treatment of
chronic low-back pain. The rate of treatment discontinua-
tion (4/42, 9%), falls well within that reported for both
drugs under study [14, 21–26]. We could also show that the
relative efﬁcacy of either monotherapy seems to correlate
well with the outcome of the LANSS score and that
combination of celecoxib and pregabalin proved to be
superior to either single agent, with comparable side-
effects and reduced mean consumption of any single drug
(calculated as mean administered dosage per patient
weight).
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